

**Exhibit 1**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**(Dollars in thousands)**

	As of December 31, 2011	As of September 30, 2012
	US\$ (Note 1)	US\$ (unaudited)
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	124,311	164,499
Short-term investments	479,173	583,085
Accounts receivable, net	200,437	178,028
Inventories	94,690	134,273
Value added tax receivables	10,833	27,937
Other receivables	16,590	16,773
Prepayments and deposits	9,792	13,532
Deferred tax assets, net	3,483	4,790
Total current assets	939,309	1,122,917
Other assets	7,330	11,161
Advances for purchase of plant and equipment	6,239	3,497
Property, plant and equipment, net	237,952	255,666
Land use rights, net	55,272	56,493
Intangible assets, net	84,029	85,451
Goodwill	128,840	172,336
Total assets	<u>1,458,971</u>	<u>1,707,521</u>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
Current liabilities:		
Short-term bank loans	50,475	52,000
Notes payable	7,013	6,108
Accounts payable	48,501	69,736
Advances from customers	20,700	16,337
Salaries payable	38,784	49,002
Other payables	67,499	106,450
Income taxes payable	16,847	20,477
Other taxes payable	7,412	6,365
Total current liabilities	<u>257,231</u>	<u>326,475</u>
Long-term bank loans	35,025	85,095
Other long-term payables	2,355	4,670
Deferred tax liabilities, net	12,925	14,974
	50,305	104,739
Shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	486,314	509,503
Retained earnings	566,184	644,143
Accumulated other comprehensive income	100,139	104,603
Treasury stock	(10,160)	—
Total shareholders' equity	1,142,492	1,258,264
Non-controlling interests	8,943	18,043
Total equity	<u>1,151,435</u>	<u>1,276,307</u>
Total liabilities and shareholders' equity	<u>1,458,971</u>	<u>1,707,521</u>

(1) Financial information is extracted from the audited financial statements included in the Company's fiscal year 2011 20F.

**Exhibit 2**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Dollars in thousands, except for share and per share data)

	Three months ended September 30,		Nine months ended September 30,	
	2011	2012	2011	2012
	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)	US\$ (unaudited)
Net revenues				
-PRC	93,500	117,721	256,682	324,855
- International	124,927	139,370	359,931	419,083
Net revenues	218,427	257,091	616,613	743,938
Cost of revenues	(98,596)	(113,134)	(273,267)	(326,034)
Gross profit	119,831	143,957	343,346	417,904
Selling expenses	(41,044)	(47,628)	(115,132)	(135,116)
General and administrative expenses	(20,777)	(34,036)	(52,641)	(79,761)
Research and development expenses	(19,343)	(23,222)	(56,435)	(71,376)
Operating income	38,667	39,071	119,138	131,651
Other income, net	414	469	2,592	1,442
Interest income	6,072	7,147	13,558	22,845
Interest expense	(319)	(1,087)	(920)	(3,065)
Income before income taxes and non-controlling interests	44,834	45,600	134,368	152,873
Provision for income taxes	(7,459)	(9,108)	(14,427)	(27,474)
Net income	37,375	36,492	119,941	125,399
Less: Net income attributable to non-controlling interests	(60)	(726)	(107)	(1,039)
Net income attributable to the Company	37,315	35,766	119,834	124,360
Basic earnings per share	0.32	0.31	1.04	1.07
Diluted earnings per share	0.31	0.30	1.01	1.04
Shares used in the computation of:				
Basic earnings per share	116,770,784	117,083,942	115,181,776	116,550,514
Diluted earnings per share	119,602,158	119,895,832	118,397,031	119,571,324

**Exhibit 3**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(Dollars in thousands)**

	Three months ended September 30,		Nine months ended September 30,	
	2011	2012	2011	2012
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
<b>Cash flow from operating activities:</b>				
Net income	37,315	35,766	119,834	124,360
Adjustments to reconcile net income to net cash from operating activities	14,537	14,113	36,472	50,706
Changes in current assets and liabilities	(21,964)	9,418	(60,337)	5,707
<b>Net cash generated from operating activities</b>	<b>29,888</b>	<b>59,297</b>	<b>95,969</b>	<b>180,773</b>
<b>Cash flow from investing activities:</b>				
Acquisition cost, net of cash acquired	(2,884)	(28,749)	(6,530)	(31,488)
Capital expenditures	(19,376)	(14,409)	(63,731)	(47,244)
Proceeds from sale of short-term investments	2,991	—	93,124	144,395
Increase in short-term investments and changes in other investing activities	(38,881)	(110,039)	(191,145)	(235,528)
<b>Net cash used in investing activities</b>	<b>(58,150)</b>	<b>(153,197)</b>	<b>(168,282)</b>	<b>(169,865)</b>
<b>Cash flow from financing activities:</b>				
Proceeds from bank loans	50,469	—	85,399	52,000
Dividends paid	—	—	(34,522)	(46,401)
Proceeds from exercise of options	1,044	8,491	5,391	22,629
Cash contribution from non-controlling interests	797	—	797	506
<b>Net cash generated from financing activities</b>	<b>52,310</b>	<b>8,491</b>	<b>57,065</b>	<b>28,734</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>24,048</b>	<b>(85,409)</b>	<b>(15,248)</b>	<b>39,642</b>
Cash and cash equivalents at beginning of period	99,614	247,985	137,502	124,311
Effect of exchange rate changes on cash	1,123	1,923	2,531	546
<b>Cash and cash equivalents at end of period</b>	<b>124,785</b>	<b>164,499</b>	<b>124,785</b>	<b>164,499</b>

**Exhibit 4**
**MINDRAY MEDICAL INTERNATIONAL LIMITED**
**RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES**

(Dollars in thousands, except for share and per share data)

	Three months ended September 30,		Nine months ended September 30,	
	2011	2012	2011	2012
	(unaudited) US\$	(unaudited) US\$	(unaudited) US\$	(unaudited) US\$
<b>Non-GAAP net income</b>	42,466	50,135	134,528	150,029
<i>Non-GAAP net margin</i>	19.4%	19.5%	21.8%	20.2%
Amortization of acquired intangible assets	(1,774)	(1,630)	(5,324)	(4,894)
Deferred tax impact related to acquired intangible assets	34	59	102	177
Dispute related legal fees	(262)	—	(262)	—
Dispute charges	—	(9,700)	—	(9,700)
Share-based compensation	(3,149)	(3,098)	(9,210)	(11,252)
GAAP net income	37,315	35,766	119,834	124,360
<i>GAAP net margin</i>	17.1%	13.9%	19.4%	16.7%
Non-GAAP basic earnings per share	0.36	0.43	1.17	1.29
Non-GAAP diluted earnings per share	0.36	0.42	1.14	1.25
GAAP basic earnings per share	0.32	0.31	1.04	1.07
GAAP diluted earnings per share	0.31	0.30	1.01	1.04
Shares used in computation of:				
Basic earnings per share	116,770,784	117,083,942	115,181,776	116,550,514
Diluted earnings per share	119,602,158	119,895,832	118,397,031	119,571,324
<b>Non-GAAP operating income</b>	43,852	53,499	133,934	157,497
<i>Non-GAAP operating margin</i>	20.1%	20.8%	21.7%	21.2%
Amortization of acquired intangible assets	(1,774)	(1,630)	(5,324)	(4,894)
Dispute related legal fees	(262)	—	(262)	—
Dispute charges	—	(9,700)	—	(9,700)
Share-based compensation	(3,149)	(3,098)	(9,210)	(11,252)
GAAP operating income	38,667	39,071	119,138	131,651
<i>GAAP operating margin</i>	17.7%	15.2%	19.3%	17.7%
<b>Non-GAAP gross profit</b>	121,174	145,171	347,367	421,416
<i>Non-GAAP gross margin</i>	55.5%	56.5%	56.3%	56.6%
Amortization of acquired intangible assets	(1,151)	(963)	(3,448)	(2,889)
Share-based compensation	(192)	(251)	(573)	(623)
GAAP gross profit	119,831	143,957	343,346	417,904
<i>GAAP gross margin</i>	54.9%	56.0%	55.7%	56.2%
<b>Non-GAAP selling expenses</b>	(39,334)	(45,786)	(109,783)	(129,624)
<i>Non-GAAP as % of total revenues</i>	18.0%	17.8%	17.8%	17.4%
Amortization of acquired intangible assets	(623)	(667)	(1,876)	(2,005)
Share-based compensation	(1,087)	(1,175)	(3,473)	(3,487)
GAAP selling expenses	(41,044)	(47,628)	(115,132)	(135,116)
<i>GAAP as % of total revenues</i>	18.8%	18.5%	18.7%	18.2%
<b>Non-GAAP general and administrative expenses</b>	(19,546)	(23,735)	(50,216)	(66,153)
<i>Non-GAAP as % of total revenues</i>	8.9%	9.2%	8.1%	8.9%
Dispute related legal fees	(262)	—	(262)	—
Dispute charges	—	(9,700)	—	(9,700)
Share-based compensation	(969)	(601)	(2,163)	(3,908)
GAAP general and administrative expenses	(20,777)	(34,036)	(52,641)	(79,761)
<i>GAAP as % of total revenues</i>	9.5%	13.2%	8.5%	10.7%
<b>Non-GAAP research and development expenses</b>	(18,442)	(22,151)	(53,434)	(68,142)
<i>Non-GAAP as % of total revenues</i>	8.4%	8.6%	8.7%	9.2%
Share-based compensation	(901)	(1,071)	(3,001)	(3,234)
GAAP research and development expenses	(19,343)	(23,222)	(56,435)	(71,376)
<i>GAAP as % of total revenues</i>	8.9%	9.0%	9.2%	9.6%

**Exhibit 5****MINDRAY MEDICAL INTERNATIONAL LIMITED****RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION****(Dollars in thousands)**

	Three months ended		Nine months ended	
	September 30,		September 30,	
	2011	2012	2011	2012
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
GAAP net income	37,315	35,766	119,834	124,360
Interest income	(6,072)	(7,147)	(13,558)	(22,845)
Interest expense	319	1,087	920	3,065
Provision for income taxes	7,459	9,108	14,427	27,474
Earnings before interest and taxes ("EBIT")	39,021	38,814	121,623	132,054
Depreciation	6,588	6,557	16,849	20,598
Amortization	2,773	2,963	7,642	8,755
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	<u>48,382</u>	<u>48,334</u>	<u>146,114</u>	<u>161,407</u>